Comparison of pegfilgrastim and daily G-CSF for CD34+ cell mobilization in healthy donors and post-transplant engraftment: The Pegfilgrastim-23 Study.
Hatase Masanao M, Goto Hideki H, Shimizu Hiroaki H, Toya Takashi T et al.
Pegfilgrastim (Peg-G), a long-acting formulation of granulocyte colony-stimulating factor (G-CSF), enables single-dose administration and effectively mobilizes CD34+ cells into the peripheral blood of healthy donors undergoing allogeneic hematopoietic stem cell transplantation. However, prospective comparisons with conventional daily G-CSF (Daily-G) regarding mobilization efficacy and safety remain limited. Moreover, no previous studies have compared the differentiation profiles of CD34+ cells mobilized by these two agents. In this multicenter, prospective observational study, we assessed the efficacy, kinetics, safety and differentiation profiles of mobilized CD34+ cells induced by either 7.2 mg dose of Peg-G on day 1 (n = 29) or Daily-G at 400 μg/m2/day from day 1 (n = 31) in 60 healthy related donors scheduled to undergo CD34+ cell collection. Hematopoietic engraftment was also evaluated in 60 recipients following infusion of the collected peripheral blood stem cells. Of the 60 enrolled donors, 50 were evaluable for peripheral blood CD34+ cell counts. The mean CD34+ cell counts were 85.6 ± 48.0 × 10⁶/L in the Peg-G group and 84.6 ± 42.4 × 10⁶/L in the Daily-G group, with no significant difference between the groups (P = .992). Similar findings were observed in the analyses stratified by collection on days 4 and day 5. No significant differences were observed in the differentiation profiles of mobilized CD34⁺ cells. The kinetics of peripheral blood cell counts were generally comparable between the groups in both the day 4 and day 5 collection cohorts, except for a higher white blood cell count on day 4 in the Peg-G group among donors collected on day 5. In exploratory analyses, CD34⁺ cell mobilization efficacy was not correlated with day 4 serum G-CSF concentrations, donor age, body weight, body mass index, or body surface area in either of the treatment groups. Adverse events were common but predominantly consisted of pain-related symptoms that were manageable with supportive care. Grade 3 adverse events included liver dysfunction in three donors and hypertension in one. All laboratory abnormalities and clinical symptoms resolved by the follow-up assessment, and no grade ≥4 adverse events were observed in any donor. Median times to neutrophil engraftment were 16 and 15 days in the Peg-G and Daily-G groups, respectively (P = .73), and those to platelet engraftment were 30 and 27 days, respectively (P = .68). Single-dose 7.2-mg Peg-G and conventional Daily-G resulted in comparable peripheral blood CD34⁺ cell mobilization and differentiation profiles of mobilized CD34⁺ cells in healthy related donors, with generally manageable safety profiles. No significant differences in the time to neutrophil or platelet engraftment were observed between recipients in the two groups. These findings suggest that both mobilization strategies are clinically applicable and that regimen selection may be tailored according to drug-specific characteristics and donor convenience.